 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Havent seen a thread on SI for WPI...Thought Id start one up and see what SI'ers think...Included are an outline of the co's business along with recent press releases. I will not incluse financial nor sec filings. If interested in more info. do a little ground stomping of your own. If you fail to come with anything, email me and I will be more than happy to aid you in your search. happy trading, Israel Watson Pharmaceuticals manufactures off-patent medications and develops advanced drug-delivery systems primarily designed to enhance the therapeutic benefits of drug compounds. It produces 53 off-patent products, including analgesics and oral contraceptives, and agents that treat both the central nervous system and cardiovascular system and that regulate hormones. The company is also developing hormone-replacement-therapy agents and pharmaceuticals that may treat psoriasis, vitiligo, skin infections, dermatoses, acne, and genital warts. CORONA, Calif., Dec. 29 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) announced today that its wholly owned subsidiary, Royce Laboratories, Inc., has received approval from the Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) to manufacture and market Etodolac 200mg and 300mg capsules. Etodolac is the off-patent equivalent of Wyeth-Ayerst Laboratories' Lodine(R), which is a nonsteroidal anti-inflammatory drug used for the treatment of osteoarthritis and for the management of pain. Shipments are expected to begin in January 1998. "The approval of Etodolac capsules complements Royce's earlier approval of Etodolac 400mg tablets and further extends Watson's pain management product offering," commented Dr. Allen Chao, chairman and chief executive officer. The Securities and Exchange Commission (SEC) encourages companies to disclose forward-looking information so that investors can better understand a company's future prospects and make informed investment decisions. Due to changing market conditions, product competition, the nature of product development and regulatory approval processes, the achievement of forward-looking statements contained in this press release are subject to risks and uncertainties. For further details and a discussion of these risks and uncertainties, see Watson's SEC filings, including its annual report on Form 10-K. Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is engaged in the development, manufacture and sale of off-patent and proprietary pharmaceutical products. SOURCE Watson Pharmaceuticals, Inc. CO: Watson Pharmaceuticals, Inc. ST: California IN: MTC SU: PDT 12/29/97 06:30 EST prnewswire.com CORONA, Calif., Dec. 22 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced approval from the Food and Drug Administration for the oral contraceptives Trivora(R)-21 and Trivora(R)-28, off-patent tablet forms of Levonorgestrel and Ethinyl Estradiol. Watson purchased the U.S. rights to these products from G. D. Searle & Co., a subsidiary of Monsanto Co. (NYSE: MTC), as part of the recent acquisition of Searle's off-patent oral contraceptive product line. These products will extend Watson's female healthcare product line, and are expected to begin shipping during the first quarter of 1998. Additionally, Watson announced that Andrew L. Turner, 50, has been elected to its Board of Directors, increasing Watson's Board to eight members. Mr. Turner is the founder, chairman, president, and chief executive officer of Sun Healthcare Group, Inc. (NYSE: SHG), a diversified long-term care company, headquartered in Albuquerque, New Mexico. "We are very pleased to have Andrew join our Board," commented Allen Chao, Ph.D., Chairman and Chief Executive Officer of Watson. "His extensive experience in the healthcare industry will greatly benefit Watson as we enter the next stage of our growth." Mr. Turner, who has a bachelor's degree in business administration from Ohio State University, began his career in the long-term care industry in the early 1970s as the licensed administrator of a 150 bed skilled nursing facility. He went on to manage a regional nursing home chain before becoming senior vice president of operations for Hillhaven Corporation. In 1986, Mr. Turner and two partners formed Horizon Healthcare Corporation, where he served as chief operating officer before leaving to found Sun Healthcare. The Securities and Exchange Commission (SEC) encourages companies to disclose forward-looking information so that investors can better understand a company's future prospects and make informed investment decisions. Due to changing market conditions, product competition, the nature of product development and regulatory approval processes, the achievement of forward-looking statements contained in this press release are subject to risks and uncertainties. For further details and a discussion of these risks and uncertainties, see Watson's SEC filings, including its 1996 annual report on Form 10-K. Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is engaged in the development, manufacture and sale of off-patent and proprietary pharmaceutical products. SOURCE Watson Pharmaceuticals, Inc. CO: Watson Pharmaceuticals, Inc.; Food and Drug Administration ST: California IN: MTC SU: PDT PER EXE 12/22/97 06:30 EST prnewswire.com | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |